Analyst initiated coverage on Celcuity with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for CELC
Across the 28 sessions after earlier CELC headlines, the stock closed higher 16 times and lower 12 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CELC | SPY |
|---|---|---|---|
| Sep 1, 2026 | Celcuity To Participate in Upcoming Investor Conferences | +3.3% | -0.7% |
| Aug 26, 2026 | Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer | +3.0% | +0.0% |
| Aug 14, 2026 | Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update | +6.2% | -0.2% |
| Aug 6, 2026 | Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call | +0.4% | -0.2% |
| Jul 30, 2026 | Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer | +5.3% | +1.7% |
| Jul 15, 2026 | FDA Approval for REVTORPYK issued to CELCUITY INC..and 1 other headline that session | -17.6% | +0.4% |
Quantisnow market dataNASDAQ
CELC
Celcuity Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical Specialities
- Listed since
- 2017
Get push alerts for CELC
Full CELC profile on Quantisnow Follow CELC and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time